Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Palumbo

Showing results (441-450 of 497) with videos related to

Pageof 50
Sort By:
Leukemia|July 17, 2014
Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survivalS Ferrero, M Ladetto, D Drandi, et al.
Leukemia|June 4, 2011
Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapyF Cavallo, S Bringhen, G Milone, et al.
British Journal of Haematology|October 2, 2014
Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromesFabio Efficace, Gianluca Gaidano, Massimo Breccia, et al.
Cell Death & Disease|October 18, 2023
MacroH2A1.1 as a crossroad between epigenetics, inflammation and metabolism of mesenchymal stromal cells in myelodysplastic syndromesC Giallongo, I Dulcamare, S Giallongo, et al.
Leukemia Research|June 30, 2015
Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromesG Caocci, M T Voso, E Angelucci, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 25, 2025
Disease Phenotype Significantly Influences the Outcome After Discontinuation of Ruxolitinib in Chronic Phase MyelofibrosisFrancesca Palandri, Massimo Breccia, Erika Morsia, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|November 26, 2018
The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of HBx N terminus in vitroR Salpini, M Surdo, M F Cortese, et al.
Leukemia|July 30, 2011
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group studyS K Kumar, J H Lee, J J Lahuerta, et al.
International Journal of Molecular Sciences|November 9, 2024
Translational Research on Azacitidine Post-Remission Therapy of Acute Myeloid Leukemia in Elderly Patients (QOL-ONE Trans-2)Esther Natalie Oliva, Maria Cuzzola, Matteo Della Porta, et al.
Blood Advances|June 11, 2026
A dynamic prognostic model for Polycythemia Vera long-terms outcomes in patients treated with RuxolitinibFrancesca Palandri, Alessandra Dedola, Giovanni Caocci, et al.
Pageof 50

Showing results (441-450 of 497) with videos related to

Sort By:
Pageof 50
Leukemia|July 17, 2014
Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survivalS Ferrero, M Ladetto, D Drandi, et al.
Leukemia|June 4, 2011
Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapyF Cavallo, S Bringhen, G Milone, et al.
British Journal of Haematology|October 2, 2014
Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromesFabio Efficace, Gianluca Gaidano, Massimo Breccia, et al.
Cell Death & Disease|October 18, 2023
MacroH2A1.1 as a crossroad between epigenetics, inflammation and metabolism of mesenchymal stromal cells in myelodysplastic syndromesC Giallongo, I Dulcamare, S Giallongo, et al.
Leukemia Research|June 30, 2015
Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromesG Caocci, M T Voso, E Angelucci, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 25, 2025
Disease Phenotype Significantly Influences the Outcome After Discontinuation of Ruxolitinib in Chronic Phase MyelofibrosisFrancesca Palandri, Massimo Breccia, Erika Morsia, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|November 26, 2018
The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of HBx N terminus in vitroR Salpini, M Surdo, M F Cortese, et al.
Leukemia|July 30, 2011
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group studyS K Kumar, J H Lee, J J Lahuerta, et al.
International Journal of Molecular Sciences|November 9, 2024
Translational Research on Azacitidine Post-Remission Therapy of Acute Myeloid Leukemia in Elderly Patients (QOL-ONE Trans-2)Esther Natalie Oliva, Maria Cuzzola, Matteo Della Porta, et al.
Blood Advances|June 11, 2026
A dynamic prognostic model for Polycythemia Vera long-terms outcomes in patients treated with RuxolitinibFrancesca Palandri, Alessandra Dedola, Giovanni Caocci, et al.
Pageof 50